Global Biosimilar Market Trends & Opportunities: 2015 Edition

Transcription

1 Global Biosimilar Market Trends & Opportunities: 2015 Edition

2 Global Biosimilar Market Trends & Opportunities: 2015 Edition BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers. We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use How To Buy information on the last page of this document. We look forward to being of service to you. If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf. Phone: +44 (0) or reportstore@bioportfolio.com 2

3 Global Biosimilar Market Trends & Opportunities: 2015 Edition Scope of the Report The report titled Global Biosimilar Market: Trends & Opportunities (2015 Edition) analyzes the global biologics market, with exhaustive discussion on demand of Biosimilars with increase in patent expiry of innovator drugs. The key market challenges recognized by the analysts and the major trends biosimilar market are presented in the report. Further, key manufacturers of Biosimilars like Sandoz, Teva, Hospira and Dr. Reddy s Lab are profiled in the report. Product Coverage? Recombinant Glycosylated Biosimilars (EPO,mAb,Follitropin)? Humira, Enbrel, Remicade, Herceptin? Recombinant Non-Glycosylated Biosimilars (Insulin,G-csf,Interferons,hGh) Company Coverage? Sandoz(Novartis)? Hospira? Teva? Dr. Reddy s Lab Executive Summary Rising budgetary pressures to reduce healthcare expenditures, patent expiries of blockbuster drugs, growing demand for cost-effective alternatives, increasing aging population, conductive government initiatives and rising incidences of various diseases are significant factors that are responsible for the growth of global biosimilar market (2013 to 2018). On the other hand stringent regulatory environment in some countries, high manufacturing complexities, costs, and presence of low priced generic drugs and high-entry barriers are considered to hinder the market growth. Emerging pharmaceutical market and less stringent government regulatory frameworks in few countries can provides some of the major opportunities for biosimilars market. In addition, increased collaboration between manufacturing companies and outsourcing of biosimilar products are key trends for biosimilars market. The biosimilar products market is segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. Globally there are 280 biosimilars in pipeline and their clinical trials are increasing at a rate of 20% annually. The report titled The Global Biosimilar Market: Trends & Opportunities ( ) provides an in-depth analysis of the growing Biosimilar Market with detailed analysis of market sizing and growth, market share and 3

4 economic impact of the industry. The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall Biosimilars industry has also been forecasted for the period , taking into consideration the previous growth patterns, the growth drivers and the current and future trends. Further, key players of the industry like Sandoz, Teva, Hospira and Dr. Reddy s Lab are profiled. Additional Details Publisher : Daedal Research Reference : Number of Pages : 80 Report Format : PDF Publisher Information : Daedal Research has created a name for itself as one of the leading global knowledge service providers of choice. We offer a blend of the best strategic consulting and market research solutions, which promise data rich, cost effective, and highly insightful analysis to help our clients with perfect answers to their important business queries. We are a research and consulting firm specialized in providing research reports and customized business research and analysis. Our success parameter is very simple - impact of our services on our clients' business. Daedal Research is the final destination to all businesses problems covering business intelligence, research and analytics. 4

5 Table Of Contents for Global Biosimilar Market Trends & Opportunities: 2015 Edition 1. Executive Summary 2. Global Biosimilar Market 2.1 Overview of Biosimilar Market History Prescription of Biosimilars Naming of Biosimilars Determination of Biosimilarity Differences between Biosimilar and Original Drugs Manufacture of Biosimilars Safety, Efficacy, Quality Variability in Biosimilars 2.1.9Regulating Biosimilars Approval Pathways of Biosimilars Market Segmentation by Therapeutic Area 3. Global Biosimilar Market: Sizing and Growth 3.1 Biosimilar Market Size: Forecasted Biosimilar market Size : Biosimilar Market Analysis: By Geography 4.1 Asia-Pacific4.1.1 China4.1.2 India4.1.3 South Korea, Taiwan, ASEAN Latin America4.1.5 Brazil4.1.6 Mexico4.1.7 Argentina4.2 Europe 4.3 U.S.A 5. Biosimilar Market: Product Analysis 5.1 Recombinant Glycosylated Biosimilars Market Size: Forecasted: Original epoetin (EPO) products Original follitropin product Original Monoclonal antibodies Following are biologic MAb drugs that are expected to become off-patent from 2013 to Recombinant nonglycosylated proteins5.2.1 Market Size: Forecasted Market Size: Original G-CSF products: Somatotropin Products 6. Market Dynamics of Biosimilar Market 6.1 Growth drivers Patent expiry Increase in Demand of Biologics Increase demand to lower the soaring health costs Focus On Therapeutic Research Areas (Diabetes, Cancer) including Monoclonal Antibody and Human Insulin Increase in expenditure on biologics globally 6.2 Market Challenges Efficacy issues Pharmacovigilance Safety issues Substitution Regulatory approval Barriers to competition 6.3 Market trends Mergers and acquisitions Penetration into U.S market7. Competitive Landscape: Global Biosimilar Market 8. Company profiles Global Biosimilar Market 8.1 Sandoz-Novartis Business overview Financial overview Business strategies 8.2 Hospira Business overview Financial overview Business strategies 8.3 Teva Business overview Financial overview Business strategies 8.4 Dr. Reddy s Laboratories Business Overview Financial overview Business strategieslist of Figures and TablesFigure 1 : Original And Biosimilar MedicineFigure 2 : Original And Biosimilar MedicineFigure 3: A stir tank bioreactorfigure 4: Biosimilars Omnitrope and AccofilTable 1: List of Biosimilars approved by EMAFigure 5: Global Biosimilar Market ( )-sales-U.S$ BillionFigure 6: Biosimilar Products Market Share (2013)Figure 7: Global Biosimilar Market Sales ( ) in U.S$ BillionFigure 8: Global biosimilar market share by geography (2013)Figure 9: Biosimilar uptake across countries in Europe in 2013Figure 10: Biosimilar Market - Recombinant Glycosylated Products Sales ( ) - US$ BillionFigure 11: Biosimilar Market - Recombinant Glycosylated Products Sales ( ) - US$ BillionFigure 12: Biosimilar Market Epoeitin and Follitropoin Sales ( ) - US$ BillionFigure 13: biosimilar monoclonal antibody market-2013 to 2018-U.S$ BillionTable 2: Biosimilars of bevacizumab in developmenttable 3: Biosimilars of Adalimumab in developmenttable 4: Biosimilar of Entracept Approved for DevelopmentTable 5: Biosimilar of Trastuzumab Approved or in DevelopmentFigure 14: Biosimilar recombinant non-glycosylated Market ( )- Sales U.S$ BillionFigure 15: Biosimilar recombinant nonglycosylated Market ( ) Sales-U.S$ BillionFigure 16: Biosimilar G-CSF Market ( )-Sals-U.S$ BillionFigure 17: Blockbuster innovator drug market sales-2013-u.s$ BillionTable 6: Blockbuster innovator drugs scheduled patent expiriesfigure 18: Global biologics sales and growth: Table 7: Increase in sales of top six biologic drugs Figure 19: Potential Cost Savings across Biologic ClassesFigure 20: Core Therapy Areas of biologics Sales-2013-U.S$ BillionFigure 21: Mortality rate of cancer patients-2012figure 22: Global spending on biologics: U.S$ BillionTable 8: Competitive landscape of key biosimilars playersfigure 23: Global Biosimilar Players market share: 2013Table 9: characterization of biosimilar players on basis of investmental capabilities and developmental expertisefigure 24: Sandoz- Biosimilars net revenue: (US$ Million)Figure 25: Hospira Net Revenue: (US$ Million)Figure 26: Teva s net revenue of oncology and women health products: (US$ Million)Figure 27: Dr. Reddy s Lab s Proprietary Products Net Revenue: (US$ Million) 5

6 How to Buy... Global Biosimilar Market Trends & Opportunities: 2015 Edition Option 1 - Online Go to our website and pay online with any major debit or credit card: Option 2 - Request a Proforma Invoice Fill in the details below, and either Scan this page and it to us at reportstore@bioportfolio.com or Fax it to us at +44 (0) We will send you a Proforma Invoice and deliver your report on settlement. Your Name: Job Title: Your Your Contact Phone: Company Name: Address: Post/Zip Code: Country: P.O. Number: Any Other Instructions: Pricing Options: (please tick one) $800 Single User Price $1600 Global License Price Payment Options: (please tick one) Online Credit Card (we will you the invoice with a payment link) Direct Wire Transfer (we will you the invoice with our bank details) Authorising Signature: Option 3 - Phone Us on +44 (0) We will be delighted to give you our personal attention. 6